<DOC>
	<DOCNO>NCT02783599</DOCNO>
	<brief_summary>The purpose study evaluate potential biomarkers method action , efficacy safety olaratumab participant soft tissue sarcoma ( STS ) .</brief_summary>
	<brief_title>A Study Olaratumab ( LY3012207 ) Participants With Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Have histologically confirm diagnosis STS olaratumab doxorubicin would appropriate therapy . Participants diagnosis Grade 1 liposarcoma eligible histological radiographic evidence evolution aggressive disease . Participants Kaposi 's sarcoma gastrointestinal stromal tumor ( GIST ) exclude . Participants must potentially resectable disease ( assess study investigator ) primary tumor lesion deem amenable serial biopsy . Have consent undergo mandatory serial peripheral whole blood tumor tissue sample . Have active central nervous system ( CNS ) leptomeningeal metastasis ( brain metastasis ) time enrollment . Participants history CNS metastasis previously treat curative intent ( example , stereotactic radiation surgery ) progress followup imaging , asymptomatic least 60 day receive systemic corticosteroid or/anticonvulsants , eligible . Participants sign symptom neurological compromise appropriate radiographic imaging perform enrollment rule brain metastasis . Have receive prior treatment doxorubicin , epirubicin , idarubicin , and/or anthracyclines anthracenediones ; participant receive treatment olaratumab participate prior olaratumab trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>